01:04 , Jun 28, 2019 |  BC Extra  |  Financial News

June 27 Financial Quick Takes: Esperion gets $125M from Oberland in funding deal for cholesterol candidates; plus Woodford, PanTheryx and Castle

Esperion, Oberland strike funding deal ahead of bempedoic acid launch  Esperion Therapeutics Inc. (NASDAQ:ESPR) forged a funding agreement with Oberland Capital tied to revenues from the sale of products containing the biotech's cholesterol-lowering candidate bempedoic...
23:26 , Jun 20, 2019 |  BC Extra  |  Financial News

New listings push IPO pace ahead of last year’s

A spate of biotech IPOs this week in which five companies raised nearly $620 million helped push the biopharma sector’s total haul from NASDAQ listings ahead of 2018’s record pace. Of the five to price...
18:54 , Jun 19, 2019 |  BC Extra  |  Financial News

June 19 Financial Quick Takes: Stoke rises after IPO; plus Polaris, Woodford, follow-ons

Stoke catches fire after pricing upsized IPO  Genetic diseases company Stoke Therapeutics Inc. (NASDAQ:STOK) gained $7.57 (42%) to $25.57 in its first day of trading Wednesday after raising $142 million in its IPO. The company...
00:29 , May 25, 2019 |  BC Extra  |  Financial News

New IPO filings include BridgeBio, Dermavant, Prevail, Atreca, Akero

In a week in which two biotechs went public and a third opted for a billion-dollar takeout instead of an IPO, five companies filed on Friday to list on NASDAQ in IPOs that could raise...
18:49 , May 23, 2019 |  BC Extra  |  Financial News

May 23 Financial Quick Takes: NYSE to lower fees for biotechs; plus Guardant and more

NYSE proposes lower fees for prerevenue biotechs  For biotech companies with a market cap of at least $200 million and annual revenues of $5 million or less, the New York Stock Exchange proposed in an...
17:02 , May 23, 2019 |  BC Extra  |  Financial News

How Bicycle, Ideaya fared in debuts as they join 2019’s growing IPO class

A pair of newly listed biotechs trended in opposite directions during first-day trading Thursday. Bicycle slipped 14% after pricing its IPO at the bottom end of its proposed range, while Ideaya was up 12% after...
22:45 , Apr 29, 2019 |  BC Extra  |  Financial News

April 29 Quick Takes: Sirnaomics, Codiak, Cortexyme, Milestone, NextCure, Applied Therapeutics, Magenta

Sirnaomics closes $47M series C  RNAi therapeutics company Sirnaomics Inc. (Gaithersburg, Md.) raised $22 million in a series C2 round led by Hong Kong-based CR-CP Life Sciences Fund, closing out its series C round for...
14:31 , Apr 26, 2019 |  BC Extra  |  Financial News

Schizophrenia therapy developer Karuna among four biotechs to file for IPOs

Weeks after completing its $80 million series B round, antipsychotic therapy developer Karuna said it has filed confidential documentation with the SEC for a planned IPO. The company was one of four to unveil plans...
15:54 , Apr 17, 2019 |  BC Extra  |  Financial News

Turning Point gains after pricing upsized $166.5M IPO

Turning Point shares jumped $10.90 (61%) to $28.90 in their first day of trading Wednesday after the company raised $166.5 million in an upsized IPO priced late Tuesday. Turning Point Therapeutics Inc. (NASDAQ:TPTX) sold 9.3...
13:48 , Mar 22, 2019 |  BC Extra  |  Financial News

Oncology company Turning Point seeking $100M IPO

Five months after raising an $80 million mezzanine round, cancer company Turning Point is aiming to reap $100 million in a NASDAQ listing that will fund a registrational trial. Turning Point Therapeutics Inc. (San Diego,...